UBS AM’s aTyr Pharma ATYR Stock Holding History

UBS AM’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2K	Hold	2,011	–	–	﹤0.01%	3602
2026 Q1	$1.57K	Buy	+2,011	New	+$1.7K	﹤0.01%	3637

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM's ATYR Position: Q2 2026 in Review

UBS AM held its aTyr Pharma (ATYR) position steady in Q2 2026 at 2,011 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3602.

UBS AM first reported a position in ATYR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.57K in Q1 2026. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

UBS AM held 2,011 shares of aTyr Pharma worth $1.2K as of Q2 2026.
UBS AM left its aTyr Pharma share count unchanged in Q2 2026.
aTyr Pharma made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3602 holding.
UBS AM first reported a position in aTyr Pharma in Q1 2026 and has held it in 2 quarters since.
UBS AM's aTyr Pharma position peaked at $1.57K in Q1 2026.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.